What's new?
10/07/2018

Paris, France, July 10th. 2018. Sofinnova Partners, a leading venture capital firm specialized in Life Sciences, today announced that Otsuka Holdings is acquiring its portfolio company ReCor Medical, a medical device company specialized in the treatment of hypertension. The terms of the acquisition are being withheld due to non-disclosure obligations.

ReCor Medical was created in 2009 by Sofinnova Partners, Mano Iyer – who was then entrepreneur-in-residence at Sofinnova Partners and now Chief Operating Officer of ReCor – and Professor Jacques Seguin, MD, who became a large private investor in ReCor. Prof. Seguin was previously founder and CEO of CoreValve, a past Sofinnova portfolio company and a leader in the transcatheter valve replacement space, which was sold to Medtronic. Sofinnova Partners was the sole venture capital investor in ReCor Medical and remained its largest shareholder until the sale to Otsuka.

ReCor Medical is an innovative medical device company that developed the Paradise System, a proprietary ultrasound ablation system for renal denervation (RDN). RDN is a new potential therapeutic approach for the treatment of hypertension, one of the most prevalent medical conditions. ReCor recently announced positive results of its landmark RADIANCE-HTN SOLO hypertension study at EuroPCR 2018.

Antoine Papiernik, Managing Partner at Sofinnova Partners and ReCor Board Member, said: “ReCor perfectly illustrates our investment strategy: we worked hand-in-hand with Mano Iyer to create the business vision and plan for ReCor. We then founded and funded the company, and opened our network of experts, key opinion leaders and board members to help grow it. We brought trusted entrepreneurs Jay Watkins as Chairman and Andy Weiss as CEO to help guide and operate the company through to a corporate transaction to our partner Otsuka.”

Jay Watkins, Chairman of ReCor Medical said: “Sofinnova Partners remains one of few VCs willing to fund early-stage med-tech ventures targeting large and important new markets. The firm played a critical role throughout ReCor’s life, and has proven to be a reliable, value-added partner for the company. The field of renal denervation has been a complex one over the last few years with periods of euphoria and periods of doubt. Sofinnova Partners’ support remained constant throughout, helping to build a strong partnership with Otsuka and then navigate through the challenges to a very successful trade sale.”

Mano Iyer, Founder and COO of ReCor Medical added: “ReCor is a success story because Sofinnova Partners, consistent with its philosophy, saw the value of an opportunity which did not yet exist. It had the vision to create and fund the company, not only in the very beginning, but also during the critical early years. Despite the dramatic swings in the field, Sofinnova Partners’ confidence in me and in the management team was essential to keep us motivated when others lost hope. This great exit is therefore particularly sweet.”

Andrew M. Weiss, CEO of ReCor Medical adds: “I came to ReCor thanks to Antoine Papiernik’s introduction to the company. With his help, our team developed the partnership with Otsuka and was able to remain focused on value creation. The recent announcement of our positive RADIANCE-HTN SOLO study results and now the merger with Otsuka demonstrate that our teamwork with Sofinnova Partners was successful. We now have an opportunity to transform the treatment of hypertension and benefit millions of potential patients while providing a solid return for our investors. I look forward to continuing to work to make this technology a possible standard of care in hypertension treatment”.

For more information, please contact:
SOFINNOVA PARTNERS
International: Anne Rein
Tel: +33 6 03 35 92 05
e-mail: anne.rein@strategiesimage.com
United States: Kate Barrette
Tel: +1 212 223 0561
e-mail: kbarrette@rooneyco.com

About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together a team of professionals from all over Europe, the US and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a lead or cornerstone investor in seed, start-ups, corporate spin-offs and late stage companies. It has backed nearly 500 companies over more than 45 years, creating market leaders around the globe. Today, Sofinnova Partners has over €1.9 billion under management. For more information: www.sofinnova.fr

About ReCor Medical, Inc.
ReCor Medical is a medical device company that designs and manufactures the Paradise System, a proprietary ultrasound ablation system for renal denervation (RDN). RDN is a new potential therapeutic approach for the treatment of hypertension, one of the most prevalent medical conditions. The Paradise System is approved for sale in the EU and bears a CE mark, but is not approved for sale in the United States. The System’s intravascular catheters denervate renal nerves by combining the protection of water-based cooling of the renal artery with high intensity ultrasound energy for circumferential renal nerve ablation. The Paradise System has been studied in clinical trials of approximately 300 patients to date. Following the positive outcomes of the RADIANCE-HTN SOLO trial, ReCor will continue its evaluations of Paradise in RADIANCE-HTN TRIO (a feasibility study of patients with resistant hypertension) and REQUIRE (a pivotal study of patients with resistant hypertension in Japan and Korea), and launch the RADIANCE II pivotal study (a study of patients with moderate hypertension) in the United States and Europe.
http://www.recormedical.com/

About Otsuka Holdings Co., Ltd. and Otsuka Medical Devices Co., Ltd.
Otsuka Holdings Co., Ltd. is the holding company of the Otsuka group, a global healthcare group headquartered in Tokyo, Japan. With operations in pharmaceuticals, nutraceuticals, medical devices and other health-related businesses, the group generated worldwide sales of JPY1,240 billion in the fiscal year ended December 2017.
http://www.otsuka.com/en/

Established in 2011, Otsuka Medical Devices Co., Ltd. is a fully-owned subsidiary of Otsuka Holdings and one of its core operating subsidiaries. Otsuka Medical Devices focuses on the development and commercialization of endovascular devices that provide new therapeutic options in areas where patient needs cannot be met through pharmaceutical or other conventional treatment.
Otsuka Medical Devices conducts the REQUIRE trial for renal denervation in hypertensive patients (n=140), who are uncontrolled on 3 or more medications including a diuretic, in Japan and Korea through its subsidiary JIMRO Co., Ltd.
http://www.omd.otsuka.com/en/

07/03/2017

Ghent, Belgium, March 7, 2017 – AgroSavfe NV, a Belgium-based agro-biotech company, announced today that it extended its Series B financing round to €11 million.
The funds will be used to accelerate the development of the Company’s novel Agrobodies® as a new generation of biopesticides and to roll out the international registration process. Agrobodies® are small proteins that are designed and formulated to specifically bind to essential target molecules of crop pests and diseases. AgroSavfe has generated Agrobodies® with antifungal activity and is developing these into a novel class of biofungicides. The company is pursuing an ambitious global product development program from its R&D centre at the Technologiepark in Ghent.
Sofinnova Partners joins earlier investors Agri Investment Fund, Biovest, Gimv, Globachem, Madeli Participaties, PMV, Qbic and VIB.
“We are very impressed with the potential of the Agrobody technology. Agro chemicals, and in particular fungicides and insecticides, are huge markets that biologicals can address if they can be scaled up and produced at competitive cost compared to chemical compounds. This is central to our investment philosophy for Sofinnova IB I, our new fund in industrial biotech, that is dedicated to renewable chemistry.” said Denis Lucquin, Managing Partner of Sofinnova Partners. Lieven De Smedt, chairman of the board of AgroSavfe adds: “Started in 2013 as a spin off from VIB, AgroSavfe has now become a truly international AgTech company with a proven technology platform, an experienced team and a Board with top-league seasoned investors and entrepreneurs. Needless to say that it is a great pleasure that Denis joins our new Board to help AgroSavfe to become a world player in biopesticides, serving both conventional and biological farming.”
About AgroSavfe NV
AgroSavfe NV, a Belgian Agro-Biotech company, established as a spin-off from VIB, develops camelid binding domains, or Agrobodies®, for diverse applications in agriculture. AgroSavfe has demonstrated that its Agrobodies® provide control of a broad range of plant pathogenic fungi and is developing a new generation of biopesticides.

About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together 12 highly experienced investment professionals from all over Europe, the US and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a founding and lead investor in start-ups and corporate spin-offs, and has backed nearly 500 companies over more than 40 years, creating market leaders around the globe. Today, Sofinnova Partners has over €1.6 billion under management.For more information, please visit: www.sofinnova.fr

Contact
AgroSavfe NV
Lieven De Smedt, Chairman of the Board
lieven.de.smedt@agrosavfe.com
+32 (474) 073 193

07/03/2017

Vienna, Austria, 6 March 2017 – Hookipa Biotech AG, a company pioneering a new class of immunotherapies for oncology and infectious diseases, today announces the appointment of Igor Matushansky, M.D., Ph.D. as Global Head, Research and Development. The appointment is effective from today.

Dr. Matushansky joins Hookipa from Daiichi Sankyo, where he was the Global Head of Translational Development for Oncology. He led Daiichi Sankyo’s international research unit focused on early oncology therapeutic programs, strategy and development, and was accountable for development activities from post-target identification basic science research to first-in-man trials and proof-of-clinical concept. Prior to that, Dr. Matushansky was at Novartis where he was Global Head for Clinical and Scientific Development at its Gene & Cell Therapy Unit as well as a Global Clinical Program Lead within Novartis’ Oncology Translational Medicine Unit.
Before being recruited to the pharmaceutical industry, Dr. Matushansky was a Professor at the Columbia University Medical Center where he ran an independent laboratory and clinic focusing on the molecular biology, translational opportunities and clinical trials in sarcomas. Currently he is an Adjunct Professor of Medical Oncology, Columbia University. He grew up in New York City where he received his undergraduate B.A. degree, summa cum laude, from Columbia University. He then went on to attend the Albert Einstein College of Medicine where he received his MD as well as a PhD in Molecular Biology. He performed his Internal Medicine residency at New York Presbyterian Hospital – Weill Cornell Medical Center and then completed a fellowship in Medical Oncology as well as a post-doctoral research fellowship in Cancer Biology at the Memorial Sloan Kettering Cancer Center.
Commenting on the appointment, Hookipa’s CEO, Mr. Joern Aldag said: “Dr. Matushansky’s valuable experience heading up R&D units at big pharma coupled with his significant immuno-oncology expertise will be transformative to Hookipa as we expand our Company from prophylactic to therapeutic immuno-oncology focused therapies. His impressive and extensive professional background makes him a perfect fit for our leadership team during an important time in our Company’s growth. I look forward to working together to achieve our goals and strategic priorities for 2017 and beyond.”

Dr. Matushansky said, “TheraT® has real potential both alone and in combination with other immune-modulators and/or targeted therapies to improve not only the current clinical outcomes but the quality of life for a wide array of cancer patients. It’s an exciting time to join the Hookipa team and I am very eager to share my experience in drug development to further its mission to help patients.”
About Hookipa Biotech
Hookipa Biotech is developing next-generation immunotherapies for infectious diseases and cancer using novel proprietary arenavirus vector platforms. To date, Hookipa has raised EUR 13.7 million in non-dilutive funds and EUR 37 million equity investment from internationally renowned venture capital investors including Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners. Additional information on Hookipa is available at www.hookipabiotech.com.

About Vaxwave®
Hookipa’s Vaxwave® technology presents a completely new replication-defective viral vector platform designed to overcome the limitations of current technologies. In this vector the gene encoding the viral envelope protein, normally responsible for virus entry into target cells, has been deleted and replaced with a target gene “of interest.” The resulting vectors infect target cells and stimulate very potent and long-lasting immune responses, however they can no longer replicate and are therefore non-pathogenic and inherently safe. HB-101, a cytomegalovirus (CMV) prophylactic vaccine, is in a clinical phase 1 trial and has already shown to be both safe in humans and to elicit potent antibody and T cell responses. We are confident to establish HB-101 as the best-in class CMV development program.
About TheraT®
Hookipa’s TheraT® platform is based on an attenuated replicating virus and is capable of eliciting the most potent T cell responses – a crucial step in treating patients with aggressive cancers. Significant pre-clinical data demonstrates that TheraT® is a powerful modality capable of turning “cold tumors hot” which should result in an additional layer of efficacy in the fight against solid tumors. Specifically, TheraT® has proven to be safe in animals as well as capable of eliciting > 50% antigen-specific T cell responses and strong tumor control in mice. The first clinical trial with HB-201 targeting human papilloma virus-induced head and neck cancer is currently being prepared. This immuno-oncology technology is further being leveraged to target tumor self-antigens or shared neoantigens.

Issued for and on behalf Hookipa Biotech AG by Instinctif Partners.
For further information please contact:

At the Company
Joern Aldag
Chief Executive Officer
Hookipa Biotech AG
Office@Hookipabiotech.com

Marine Popoff
Communications Analyst
Hookipa Biotech AG
Mpopoff@Hookipabiotech.com

Media enquiries
Sue Charles/ Daniel Gooch/ Alex Bannister
Instinctif Partners
hookipa@instinctif.com
+44 (0)20 7866 7905

02/03/2017

Paris, France – March 2nd, 2017 — Sofinnova Partners, a leading European venture capital firm specialized in life sciences, today announced the first closing of Sofinnova Industrial Biotech I (Sofinnova IB I*) at €106 million. The fund, dedicated to renewable chemistry, follows a series of 9 investments in the sector since 2009, and places Sofinnova Partners at the forefront of this promising emerging market.

Sofinnova IB I will be invested in start-ups along the value chain from the transformation of renewable raw materials, like agricultural waste or C02, to renewable end-products such as bio-plastics and other bio-sourced materials. It will equally look at technologies coming from advances in synthetic biology and alike. The investment thesis is based on growing market demand for innovative, renewable products leveraging non-fossil raw materials and novel technologies to produce better performing or cheaper, sustainable alternatives.

Pursuing the strategy applied consistently over the years with previous funds, Sofinnova Partners will seek to invest Sofinnova IB I as a founding and lead investor in start-ups and corporate spin-offs, in Europe and North America. The focus of the fund will consist in backing visionary entrepreneurs aiming at developing paradigm changing innovations from lab to the end users market. Sofinnova IB I will seek to invest in 8 to 10 companies during the next 3 to 4 years. It will leverage an experienced and dedicated team, initially composed of Denis Lucquin, Managing Partner, Joško Bobanovic, Partner, and Michael Krel, Principal.

For this substantial first closing, Sofinnova IB I attracted premier investors, predominantly European institutions and major international industrial players, from energy, chemical and agricultural sectors, including several returning investors from the seed fund raised in 2012 in the same sector: Sofinnova Green Seed Fund.

Denis Lucquin, Managing Partner at Sofinnova Partners, said, “We are very pleased with the success of this first closing. The experience accumulated since 2009 resonated well with the investors. With investments in the sector ranging from Avantium, developing an entirely bio-based plastic bottle and now planning an IPO on Euronext, to the most recent DNA Script, revolutionizing DNA synthesis, Sofinnova Partners stands as a pioneer investor, benefitting from an acute understanding of the dynamics at work in this emerging sector. With establishment of this entirely dedicated fund, we have reached today a further important step in our development in industrial biotech.”

* The Fund is supported by InnovFin Equity more details

 

About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together 12 highly experienced investment professionals from all over Europe, the US and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a founding and lead investor in start-ups and corporate spin-offs, and has backed nearly 500 companies over more than 40 years, creating market leaders around the globe. Today, Sofinnova Partners has over €1.6 billion under management.
For more information, please visit: www.sofinnova.fr
Press contact for SOFINNOVA PARTNERS
Anne REIN Tel: +33 6 03 35 92 05
@: anne.rein@strategiesimage.com

28/02/2017

Investment from new and current investors will be used to advance Comet’s second-generation dextrose plant in Sarnia, Ontario
Agricultural residues to be converted into high-purity dextrose for production of sustainable bio-chemicals

London, Ontario – 28 February 2017 – Comet, an industry leader in the production of high-purity cellulosic dextrose, today announced the completion of a round of equity financing led by new investor PM Equity Partner. Current investor Sofinnova Partners and new investor Bioindustrial Innovation Canada (BIC) also participated in the financing. Terms of the financing were not disclosed.

Comet’s industrial technology converts agricultural residues into high-purity dextrose for production of sustainable bio-chemicals. Comet’s cellulosic sugar is not only cost- and quality-competitive with corn or sugarcane derived products, but importantly, it does not hamper food production and has a superior carbon footprint, improving the sustainability profile of the produced biochemical. The investment will be used to advance the commercialization of Comet’s secondgeneration sugar production platform and fund construction of the company’s previously announced 60 million pounds per year dextrose facility in Sarnia, Ontario.

“We are very pleased to announce this new round of financing, with strong support from Sofinnova Partners and our new investors. The investment reflects confidence in our low-cost, high-purity cellulosic dextrose technology and enables us to deliver on a key missing piece in the value chain – a viable source of renewable sugars from non-food biomass,” said Rich Troyer, CEO of Comet.

Joško Bobanović of Sofinnova Partners commented, “We look forward to supporting the Comet management team as they take the company and the technology to the next level. Comet’s project is now well-positioned to enable profitable production of truly commercial quantities of second-generation sugars and co-products for bio-based applications.”

In March 2016, with strong support of BIC, Comet Biorefining partnered with the Cellulosic Sugar Producers Cooperative located in Western Ontario. The Ontario farmer group plans to invest in and supply corn stover and wheat straw feedstock to Comet’s commercial plant. Sandy Marshall, Executive Director of BIC noted that “The recent investment allows us to continue to support Comet Biorefining’s mission to integrate regional supply chains with innovative new technology partners and enable Sarnia-Lambton to become a leader in the development of sustainable, bio-based products.”

About Comet Biorefining
Comet Biorefining is a leading provider of sustainable, high-quality, costcompetitive cellulosic dextrose technology for applications in renewable biochemicals and biofuels. Comet Biorefining operates a demonstration scale plant in Rotondella, Italy, owned by ENEA – the Italian National Agency for New Technologies, Energy and Sustainable Economic Development. In February 2016, Comet Biorefining announced the construction of a 60 million pounds per year commercial sugar plant to come online in 2018. The company plans to build, own and operate its own plants and will strategically license its technology to select partners on a worldwide basis to meet the growing demand for bio-based products. For more information, visit www.cometbiorefining.com.

About Sofinnova Partners
Sofinnova Partners is an independent venture capital firm based in Paris, France.
For more than 40 years, the firm has backed nearly 500 companies at different stages of their development – pure creations, spin-offs, as well as turnaround situations – and worked alongside key entrepreneurs in the Life Sciences industry around the globe. With over €1.3 billion of funds under management, Sofinnova Partners has created market leaders with its experienced team and hands-on approach in building portfolio companies through to exit. For more information, please visit: www.sofinnova.fr

About PM Equity Partner
PM Equity Partner is the corporate venture and private equity investment arm of Philip Morris International. For more information, visit
www.pmequitypartner.com

About Bioindustrial Innovation Canada (BIC)
Bioindustrial Innovation Canada (BIC) is a Canadian not-for-profit organization catalyzing the commercialization of Cleantech with a focus on bio-based and sustainable chemistry-based technologies including advanced biofuels, biochemicals, biomaterials and bio-ingredients. Based in Sarnia, Ontario, the BIC mission is to create jobs and economic value sustainably in Canada. For more information, visit www.bincanada.ca

Media Contact
Janaina Topley Lira
Sustainability Consult
jtl@sustainabilityconsult.com
+32 2 347 1101

22/02/2017

PARIS, France, and CAMBRIDGE Mass. USA —February 21st, 2017—Lysogene, (the “Company” FR0013233475 – LYS) a leading, clinical-stage biotechnology company specializing in gene therapy for rare central nervous system diseases, today announces that the European Medicines Agency (EMA) has granted orphan drug designation to LYS-GM101, the Company’s gene therapy drug candidate for treatment of GM1 Gangliosidosis (GM1). The U.S. Food and Drug Administration also granted an orphan drug designation and a rare pediatric disease designation to LYS-GM101 earlier this year. “The EMA Orphan Drug Designation for LYS-GM101 is a key regulatory milestone further validating the medical plausibility of our approach,” stated Karen Aiach, Founder and Chief Executive Officer of Lysogene. “This designation will further facilitate and accelerate clinical development of our treatment. It is good news for patients suffering from this severe neurodegenerative disease and we look forward to studying this therapy further as we approach our upcoming Phase I/II clinical trial (LYS-GM101) in 2018.” LYS-GM101 is designed to replace a defective gene in the cells of GM1 patients, in order to allow for production of the functional enzyme and to prevent the progressive nature of the neurological damage caused by GM1 in humans. About the Orphan Drug Designation (ODD)
An ODD by the EMA allows a pharmaceutical company to benefit from incentives from the EU to develop a medicine for a rare disease. Applications for ODD are examined by the Committee for Orphan Medicinal Products (COMP), which adopts an opinion that is forwarded to the European Commission (EC). The EC then decides whether to grant an orphan designation for the medicine in question within 30 days of receipt of the COMP opinion. Pharmaceutical companies that obtain ODD benefit from a number of incentives, including protocol assistance, a type of scientific advice specific for designated orphan medicines, and market exclusivity once the medicine is on the market. Fee reductions are also available, depending on the status of the sponsor and the type of service required

About GM1
GM1 is an extremely severe, autosomal recessive disease caused by a mutation in the GLB1 gene encoding for the lysosomal acid beta-balactosidase (ßgal) enzyme. The resulting enzymatic deficiency leads to accumulation of GM1-ganglioside in cells. Clinical presentation is mainly neurological with rapidly progressive impairment (motor, cognitive and behavioral) leading to premature death, mostly in early childhood. It is a devastating disease for patients and families. There is currently no disease modifying treatment available.

About Lysogene
Lysogene is a clinical stage biotechnology company pioneering the basic research and clinical development of AAV gene therapy for CNS disorders with a high unmet medical need. Since 2009, Lysogene has established a solid platform and network, with lead products in Mucopolysaccharidosis Type IIIA and GM1 Gangliosidosis, to become a global leader in orphan CNS diseases. Lysogene has also obtained ODD by the EMA and FDA and rare pediatric designation by the FDA for its MPS IIIA program.
Lysogene is listed on the Euronext regulated market in Paris (ISIN code: FR0013233475)
For more information, visit www.lysogene.com.

Contacts
Media
Europe
Annie Florence
NewCap
afloyer@newcap.fr
+ 33 6 88 20 35 59
+ 33 1 44 71 00 12

Investors
Chris Maggos
LifeSci Advisors
chris@lifesciadvisors.com
+41 79 367 6254
North America
Marion Janic
RooneyPartners
mjanic@rooneyco.com
+ 1 (212) 223-4017

22/02/2017

This morning, Michael Clayman, M.D., CEO of Flexion Therapeutics (Nasdaq:  FLXN), appeared live on Fox Business News to talk about the need for new treatment options for osteoarthritis (OA) and Flexion’s lead investigational product candidate, ZilrettaTM (FX006) which is being evaluated as a potential new therapy for OA related knee pain.  A link to Mike’s interview can be found below:

http://finance.yahoo.com/video/developing-alternatives-opioids-relieve-pain-130004965.html

21/02/2017

Montreal, February 20, 2017. BioAmber Inc. (NYSE:BIOA) announced today that Jean-Francois Huc has resigned as President and CEO and Fabrice Orecchioni, the company’s COO, has been named President, effective immediately.

In his role as COO over the past four years, Fabrice has overseen the construction, start-up and operation of the manufacturing plant in Sarnia and the management of the Mitsui JV. Fabrice has also been extensively involved in the negotiations with CJ CheilJedang for the proposed China JV.

Mr. Huc, who stepped down for personal reasons, will remain a member of the board of directors and will also assume an advisory role with the management team to help ensure a smooth transition.

About BioAmber
BioAmber (NYSE: BIOA) is a renewable materials company. Its innovative technology platform combines biotechnology and catalysis to convert renewable feedstock into building block materials that are used in a wide variety of everyday products including plastics, paints, textiles, food additives and personal care products. For more information visit www.bio-amber.com

Forward-Looking Statements
This press release contains forward-looking statements, which are subject to substantial risks, uncertainties and assumptions. These statements often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may” or similar expressions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur and the timing of events and circumstances and actual results could differ materially from those projected in the forward- looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. For additional disclosure regarding these and other risks faced by BioAmber, see disclosures contained in BioAmber’s public filings with the SEC including, the “Risk Factors” section of BioAmber’s most recent Annual Report on Form 10-K and the recent quarterly reports on Form 10-Q.

BioAmber Investor Contact
Roy McDowall
Sr. VP Communication & Strategy
514-844-8000 Ext. 260
roy.mcdowall@bio-amber.com

14/02/2017

Paris, France – February 14th, 2017 – Pixium Vision, a company developing innovative bionic vision systems with the intention to allow patients who have lost their sight to lead more independent lives, today announced that the German Institute for the Hospital Remuneration System (InEK) has granted NUB (Neue Untersuchungs- und Behandlungsmethoden) Status-1 for IRIS®II, Pixium Vision’s first bionic vision system, equipped with a bio-inspired camera and a 150 electrodes epi-retinal implant with a proprietary design intended to be explantable and upgradable.
The NUB process allows negotiations between hospitals and statutory health insurances on the potential reimbursement of new medical treatments in the German statutory health insurance system (detailed information on the NUB process and Status is available at http://www.g-drg.de/G-DRG-System_2017/Neue_Untersuchungs-_und_Behandlungsmethoden_NUB). Based on NUB Status-1 for IRIS® II, ophthalmic hospitals can negotiate reimbursement coverage under the German statutory health insurance system for IRIS®II treatment for patients with advanced outer retinal degeneration due to Retinitis Pigmentosa (RP). A NUB decision is valid for one year and can be renewed annually. Khalid Ishaque, Chief Executive Officer of Pixium Vision said: “After having received the CE mark for IRIS®II, obtaining market access and reimbursement has been the main focus as we continue on our mission towards innovative treatment options. We intend to progressively expand availability across Germany as well as other regions. Obtaining the NUB Status-1 supports our ongoing efforts to bring innovations in bionic vision capabilities to patients blinded by retinal dystrophies.” The clinical centers offering IRIS®II initially include ophthalmic hospitals at the following university clinics:  Universitätsklinikum Aachen  Universitätsklinikum Bonn  Universitätsklinikum Freiburg  Universitätsklinikum Hamburg-Eppendorf  Klinikum der Universität München

Contacts
Pixium Vision
Khalid ISHAQUE, CEO
investors@pixium-vision.com
+33 1 76 21 47 46
@PixiumVision

Media Relations : Newcap Media
Annie-Florence Loyer – afloyer@newcap.fr
+33 1 44 71 00 12 / +33 6 88 20 35 59
Léa Jacquin – ljacquin@newcap.fr
+33 1 44 71 20 41

ABOUT IRIS®II
IRIS®II is a bionic vision system equipped with a bio-inspired camera and a 150 electrodes epi-retinal implant with a proprietary design intended to be explantable and eventually upgradable for patients who have lost sight due to Retinitis Pigmentosa (RP).
The Company received CE mark for IRIS®II in 2016, enabling Pixium to launch its commercial activities subject to reimbursement availabilities. CE mark approval for IRIS®II system enables the company to file for national reimbursements. The Company is working initially with public reimbursement authorities for innovative technologies for medical devices in France (under “Forfait Innovation”) and in Germany (with NUB).

ABOUT PIXIUM VISION
Pixium Vision’s mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention as well as a rehabilitation period.
The company is developing two bionic retinal implant systems. IRIS®II, the company first bionic system, obtained CE mark in July 2016. In parallel, Pixium Vision has recently completed the pre-clinical study phases for PRIMA, a sub-retinal miniaturized wireless photovoltaic implant platform, and is planning to initiate first-in-human trials.
Pixium Vision collaborates closely with academic and research partners spanning across prestigious vision research institutions including the Institut de la Vision in Paris, the Hansen Experimental Physics Laboratory at Stanford University, and Moorfields Eye Hospital in London. The company is EN ISO 13485 certified.
For more information, please visit: www.pixium-vision.com;

Disclaimer:
This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward looking statements.
Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise.
For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 “Risk Factors” of the company’s Registration Document filed with the AMF under number R16-033 on April 28, 2016 which can be found on the websites of the AMF – AMF (www.amf-france.org) and of Pixium Vision (www.pixium-vision.com).
IRIS® is a trademark of Pixium-Vision SA
Pixium Vision is listed on Euronext Paris (Compartment C). Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles.
Euronext ticker: PIX – ISIN: FR0011950641 – Reuters: PIX.PA – Bloomberg: PIX:FP

10/02/2017

Berlin, Germany, February 10, 2017 – NOXXON Pharma N.V. (Alternext Paris: ALNOX), a biotechnology company whose core focus is on cancer treatment, has today announced that Jarl Ulf Jungnelius, M.D., Ph.D. will take over the role of Chief Medical Officer. Dr. Jungnelius, who is already familiar with the company’s programs in a consulting capacity, will now increase his involvement with NOXXON, allowing for a period of overlap with Dr. Matthias Baumann whose current contract as Chief Medical Officer expires in June 2017.

Dr. Jungnelius’ career includes leadership positions at Celgene, Pfizer, Takeda and Eli Lilly & Company and significant roles in the approval of several successful oncology drugs including Abraxane®, Gemzar®, Alimta® and Revlimid®. Of particular relevance to NOXXON is his prior experience in immune-oncology and his involvement with two agents that have been approved for pancreatic cancer, one of the indications pursued in the upcoming clinical trial of NOX-A12 in combination with Keytruda® which will be conducted in collaboration with Merck & Co. / MSD.
“I am pleased to take on the role of CMO to work with the NOXXON team and excited by the opportunity to work with agents targeting the tumor microenvironment which I believe is an approach with significant potential for patients,” commented Dr. Jarl Ulf Jungnelius.

“Jarl Ulf is a great fit for NOXXON as we continue our transition to a clinical oncology company. His extensive experience in oncology clinical development in the US and Europe will be invaluable as we develop NOX-A12 to target the tumor microenvironment,” commented Dr. Aram Mangasarian, CEO of NOXXON.

“On behalf of the board I want to thank Matthias for all excellent work he has done for NOXXON Pharma across multiple programs in the last years and for the professional and pragmatic way he is managing this transition,” commented Dr. Hubert Birner, Chairman of NOXXON.

Further Information about Dr. Jarl Ulf Jungnelius
Jarl Ulf Jungnelius, M.D., Ph.D. worked at Celgene from 2007 to 2014 where he served as Vice President of Clinical Research and Development, Solid Tumors. Prior to that post Dr. Jungnelius held leadership positions at Takeda, Pfizer and Eli Lilly & Company, where he was responsible for clinical development of oncology programs as well as involved in business development. Dr. Jungnelius held important responsibilities in the clinical development of several successful oncology drugs, including Abraxane®, Gemzar®, Alimta® and Revlimid®. He is an oncologist with more than 25 years of clinical and research experience at both large pharmaceutical companies and academic organizations. Dr. Jungnelius is currently Chief Medical Officer at VAXIMM, Supervisory Board director of Isofol Medical AB, Biovica International AB and Monocl AB and has been a director at Oncopeptides AB since April 2011. He received both a Bachelor of Science degree and his M.D. from the Karolinska Institute inStockholm Sweden.
For more information, please contact:
NOXXON Pharma N.V.
Aram Mangasarian, Ph.D., Chief Executive Officer
Tel. +49 (0) 30 726 2470
amangasarian@noxxon.com

NewCap
Florent Alba
Tel. +33 (0) 1 44 71 98 55
falba@newcap.fr

About NOXXON
NOXXON Pharma N.V. is a clinical-stage biopharmaceutical company focused on cancer treatment.
NOXXON’s goal is to significantly enhance the effectiveness of cancer treatments including immunooncology approaches (such as immune checkpoint inhibitors) and current standards of care (such as chemotherapy and radiotherapy). NOXXON’s Spiegelmer® platform has generated a proprietary pipeline of clinical-stage product candidates including its lead cancer drug candidate NOX-A12, which is the subject of a clinical immuno-oncology collaboration agreement with Merck & Co. / MSD (NYSE: MRK) to
study NOX-A12 combined with Keytruda® (pembrolizumab) in pancreatic and colorectal cancer. NOXXON
is supported by a strong group of leading international investors, including TVM Capital, Sofinnova
Partners, Edmond de Rothschild Investment Partners, DEWB, NGN and Seventure. NOXXON has its
statutory seat in Amsterdam, The Netherlands and its office in Berlin, Germany. Further information can
be found at: www.noxxon.com

07/02/2017

• €22.6 m raised on Euronext Paris which combined with the €2 m issued from convertibles bonds exercised by Alto Invest, will enable Lysogene to increase its share capital up to €24.6 m
• €15 m from historical shareholders: Sofinnova Partners, BpiFrance Investissement (InnoBio) and Novo A/S
• New partner joining Lysogene: Financière Arbevel with €2 m
• Market capitalisation of approximately €82.1 m
• Offer price set at €6.80 per share corresponding to the low-range price of the Offering

Paris, France – February 7, 2017— Lysogene (the “Company”), a biotechnology company specializing in gene therapy targeting two rare CNS diseases announced today the success of its initial public offering on Compartment C of the Euronext regulated market in Paris (“Euronext Paris”), by way of an Open Price Offering (“OPO”) and a Global Placement (“Global Placement”, together with OPO, the “Offering” ), raising €22.6 m by means of a capital increase.

“We are very pleased to announce today the success of our initial public offering on Euronext Paris, which constitues a step that is a key milestone in the development of our company.” states Karen Aiach, founder and CEO of Lysogene. “This IPO will enable us to pursue the development of two drugs to treat two polysdisabling, devastating and deadly diseases of the central nervous system, which start in infancy and lead to the patients premature death. By focusing directly on the cause, our treatments aim to cure these diseases the medical needs of which are largely unsatisfied and currently uncovered. We would like to take this opportunity to thank our shareholders such as Sofinnova Partners, BpiFrance Investissement (InnoBio) and Novo A/S as well as new partners such as Financière Arbevel and Alto Invest in connection with the conversion of its convertible bonds, which have joined us during this IPO.”

“We are pleased to have supported an entrepreneur like Karen, who developed in record-time, along with her team, an innovative technology in gene therapy for the treatment of rare and deadly central nervous system diseases. This IPO tops off a unique and remarkable track-record in the Biotech sector, in order to address important unmet medical needs.” state Rafaele Tordjman de Sofinnova Partners et Chahra Louafi de BpiFrance Investissement, both members of Lysogene’s Board of Directors.

The price of the OPO and the Global Placement is €6.80 per share. 3,323,567 new shares will be issued in the context of the Offering, allowing for a capital increase of €22,600,256 (including issuance premium), up to approximately 95% of the initially envisaged capital increase without the overallotment option.

The order book is built around leading, specialist, French and european, institutional investors:
• Global Placement: total subscription demand of €22.9 m
• Open Price Offering: demand of €1.6 m
The subscription commitments as mentioned in the note d’opération have been fulfilled. The historical shareholders, Sofinnova Partners, BpiFrance Investissement (InnoBio) participated in the Offering with €15 m and a new partner joined Lysogene, Financière Arbevel, with €2 m.
On the basis of a price per share of €6.80, Lysogene’s market capitalisation is approximately €82.1 following the transaction.

The 3,323,567 shares offered within the context of the Offering will be allocated as follows:
• Global Placement: 3,091,786 shares allocated to institutional investors (representing 93.03% of the total number of shares allocated);
• OPO: 231,781 shares allocated (representing 6.97% of the total number of shares allocated);
• In respect to the OPO, A1 and A2 orders will be 100% satisfied

Lysogene’s free float will be approximately 11.69% of the share capital.
The Share Capital Increase, combined with the €2 m resulting from the conversion of the convertible bonds of Alto Invest, will enable Lysogene to increase its share capital up to €24.6 m.
Trading on Compartment C of Euronext Paris will begin at 9.00 a.m. on February 8, 2017 in the form of when-issued shares on a single listing line entitled “Lysogene – Promesses” and will be subject to delivery of the custodian’s certificate relating to the issuing of the new shares.
Clearing-settlement of the shares issued in respect of the open price offer and global placement will take place on February 9, 2017. The shares will be traded on Euronext Paris under ISIN code FR0013233475 and ticker LYS as of February 10, 2017.

As from February 8, 2017, and for a period of one-year automatically renewable period, Lysogene has entered into a liquidity contract with French broker Gilbert Dupont that complies with the code of ethics issued by the AMAFI and approved by the French AMF on March 21, 2011.
For the implementation of such contract, €300,000 in cash have been credited to the liquidity account.
Lysogene’s capital distribution after the Offering
The calculation of the free float takes into account the number of shares held by the public 6.82%, Alto Invest 2.44%, and Financière Arbevel 2.44%.

Rationale for the Offering

The purpose of the Offering is to provide the Company with additional financial resources to fund its activities and pursue the development of its technology platforms and drug candidates. The proceeds of the Offering will mainly finance:
• the completion of the Pivot Phase study in Europe and the United States of LYS-SAF302, for the treatment of MPS IIIA, with up to two-thirds of the net proceeds of the Offering,
• the completion of the Phase I/II study of LYS-GM101 for the treatment of GM1 Gangliosidosis, with up to approximately one-fourth of the net proceeds of the Offering, and
• the remainder of the net proceeds of the Offering (one-twelfth) will finance the Company’s continuing activities aside from the foregoing two R&D programs.

Indicative timetable of the IPO

February 8, 2017  Start of trading of the shares on Euronext Paris in the form of “when-issued” shares (traded under the symbol “Lysogene-Promesses”)
February 9, 2017  Clearing-settlement of the Offering
February 10, 2017  Opening of trading of the Lysogene shares on Euronext Paris under the symbol “Lysogene”

Joint Lead Managers and Bookrunners
Joint Lead Manager and Bookrunner Joint Lead Manager and Bookrunner

Identification codes for Lysogene shares
• Company name: “Lysogene”
• ISIN code: FR0013233475
• Ticker: LYS
• Compartment: Euronext Paris (Compartment C)
• Sector: 4573 – Biotechnology

How to obtain the Prospectus
Copies of the prospectus for the Offering and the admission of Lysogene shares to Euronext’s regulated market in Paris consisting of (i) the document de base approved by the French Autorité des Marchés Financiers (“AMF”) on January 9, 2017 under no. I.17-001 and (ii) the note d’opération with the summary of the prospectus, approved by the AMF on January 24, 2017 under no. 17-031, are available free of charge upon request from Lysogene (18-20 rue Jacques Dulud, 92200 Neuilly-sur-Seine) and from the Company’s (www.lysogene.com) and the AMF’s (www.amf-france.org) websites.

Risk factors
Investors are advised to read carefully the risk factors presented in Chapter 4 “Risk factors” of the document de base and especially the factors in section 4.2 “Risks arising from the Company’s business activities and products”, giving special regard to the factors in section 4.2.5 “Risks related to financing the development of the Company’s business activities” to the extent that the Company does not yet generate any revenue, and Chapter 2 “Risks related to the Offering” of the note d’opération.

About Lysogene
Lysogene is a clinical-stage biotechnology company pioneering in the basic research and clinical development of gene therapies that use vectors derived from adeno-associated viruses to treat rare and fatal central nervous system disorders in children, for which, to the best of the Company’s knowledge, no current treatment exists. Since 2009, Lysogene has established a solid platform and extensive network, along with innovative products in MPS IIIA and GM1 Gangliosidosis, to become a global leader in gene therapies for rare and fatal central nervous system diseases.

For more information, visit www.lysogene.com
About Sofinnova Partners
Sofinnova Partners is an independent venture capital firm based in Paris, France. For more than 40 years, the firm has backed nearly 500 companies at different stages of their development – pure creations, spin-offs, as well as turnaround situations – and worked alongside key entrepreneurs in the Life Sciences industry around the globe. With over €1.3 billion of funds under management, Sofinnova Partners has created market leaders with its experienced team and hands-on approach in building portfolio companies through to exit. Sofinnova Partners supports Lysogene since its seed funding in 2013.

For more information, please visit: www.sofinnova.fr

About BpiFrance Investissements
BpiFrance, a subsidiary of the French state and the Caisse des Dépôts and the entrepreneurs’ trusted partner, finances businesses from the seed phase to IPO, through loans, guarantees and equity investments.
BpiFrance also provides operational services and strong support for innovation, export, and external growth in partnership with Business France.
BpiFrance offers to businesses a large range of financing opportunities at each key step of their development, including offers adapted to regional specificities.
With its 47 regional offices (90% of decisions are made locally) BpiFrance represents a strategic tool for economic competitiveness dedicated to entrepreneurs.
BpiFrance acts as a back-up for initiatives driven by the French State and the Regions to tackle 3 goals: contributing to SME’s growth, preparing tomorrow’s competitiveness and contributing to the development of a positive entrepreneur ecosystem.
With BpiFrance, businesses benefit from a powerful, efficient and close representative, to answer all their needs in terms of financing, innovation and investment.

For more information, please visit: www.bpifrance.fr
Contacts

Lysogene
Sarah Ankri
VP Finance
sarah.ankri@lysogene.com
+33 (0)1 41 43 03 90 NewCap
Investor relations
Julie Coulot
lysogene@newcap.eu
+33 (0)1 44 71 20 40 NewCap
Media relations
Annie-Florence Loyer
afloyer@newcap.fr
+33 (0)1 44 71 94 93
Important information
This announcement does not, and shall not, in any circumstances constitute a public offering nor an invitation to the public in connection with any offer.
The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.
This announcement is an advertisement and not a prospectus within the meaning of Directive 2003/71/EC of the European Parliament and of the Council of 4 November 2003, as amended (the “Prospectus Directive”).
With respect to the member States of the European Economic Area other than France (the “Member States”, no action has been undertaken or will be undertaken to make an offer to the public of the securities referred to herein requiring a publication of a prospectus in any relevant Member State other than France. As a result, the securities may not and will not be offered in any relevant Member State other than France except in accordance with the exemptions set forth in Article 3(2) of the Prospectus Directive or in such other cases not requiring the publication by the Company of a prospectus in accordance with article 3 of the Prospectus Directive and/or regulations applicable in that Member State.
This document may not be distributed, directly or indirectly, in the United States. This document is not an offer of securities for sale nor a solicitation of an offer to subscribe securities in the United States or any other jurisdiction where such offer may be restricted. Securities may not be offered or sold in the United States absent registration under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or an exemption from registration. The shares of the Company have not been and will not be registered under the Securities Act, and the Company does not intend to make an offer to the public of its securities in the United States. Copies of this document are not being, and should not be, distributed in or sent into the United States.
This document is only being distributed to, and is only directed at, persons that (i) are located outside the United Kingdom, (ii) are “investment professionals” falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the “Order”), (iii) are persons falling within Article 49(2)(a) to (d) (“high net worth companies, unincorporated associations, etc.”) of the Order, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of Article 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as “Relevant Persons”). This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.
A prospectus, consisting of (i) the document de base registered by the French Autorité des marchés financiers (the “AMF”) on January 9, 2017 under no. I. 17-001 and (ii) a note d’opération (the “note d’opération”) including the summary of the prospectus, approved by the AMF on January 24, 2017 under no. 17-031 (the “Prospectus”). The Prospectus is available on the AMF website (www.amf-france.org) and on the Company’s website (www.lysogene.com) and may be obtained free of charge from the Company. Potential investors should review the risk factors described in the Prospectus.